Shanghai Henlius Biotech Inc (2696)
Hong Kong Stock Exchange · Hong Kong · prices in HKD · close of 21 Oct 2026
Key indicators
| Last close | HKD 53.70 |
|---|---|
| 52-week range | 47.62 – 87.10 |
| Return, 1 month / 3 months | −10.1% / −7.6% |
| Return, 1 year / 3 years | −25.0% / +390.0% |
| Trend | Below its 200-day average |
| RSI (14) | 44 |
| Volatility (1 year) | 59.2% |
| Worst drawdown (1 year) | -40.6% |
| Average daily value traded | 60.78M HKD |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Shanghai Henlius Biotech is a biopharmaceutical company based in Shanghai, China, that develops and makes biologic medicines. It focuses on monoclonal antibodies and biosimilars, which are copies of existing biologic drugs, and it also works on novel antibody therapies. Its products include treatments for cancers and autoimmune conditions, and it supplies hospitals and healthcare providers in China and through partners in other markets. The company carries out research, manufacturing and commercial activities from its base in Shanghai.
On this site Shanghai Henlius Biotech Inc appears as a stock on the Hong Kong Stock Exchange (Hong Kong), code 2696, with prices in Hong Kong dollars (HKD). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Shanghai Henlius Biotech Inc (2696) trades on the Hong Kong Stock Exchange in Hong Kong. It last closed at HKD 53.70 on 21 October 2026.
Its price-based Market X-Ray is 55 out of 100 (a fair price profile), ranking 1,112 of 2,611 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 25.0% and over the last three months it fell 7.6%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Hong Kong Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 49 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -17.6% | ||
| From 52-week high | -36.4% | ||
| Momentum | 39 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -7.6% | ||
| 6-month return | -35.3% | ||
| 12-month return, skipping the last month | -16.6% | ||
| Stability (higher is calmer) | 55 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 59.2% | ||
| Worst drawdown, 1 year (smaller is calmer) | -40.6% | ||
| Liquidity | 88 · Strong | Trades actively. | |
| Average daily value traded | 60.78M HKD | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
- Liquidity: Trades actively.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
Returns
| 1 week | +0.6% |
|---|---|
| 1 month | −10.1% |
| 3 months | −7.6% |
| 6 months | −35.3% |
| 1 year | −25.0% |
| 3 years | +390.0% |
| 5 years | – |
Signals
| 50-day / 200-day average | 61.94 / 65.17 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | Yes |
| Average daily range (ATR) | 3.56 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Hong Kong Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.